Table 1.

Trials Comparing Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers with Other Regimes in Hypertensive Patients*

TrialYearType of Patients (n)Years of Follow-up (n)Drugs ComparedEntry BP (mm Hg)BP Difference During StudyPPrimary EndpointRelative Risk95% CIOther Significant Outcome DifferencesP
UKPDS71998Hypertensive (n = 758)9Captopril vs atenolol159/93NSNACli diab event1.10.86–1.41NoneNS
Diabetes death1.270.82–1.97NS
Total mortality1.140.81–1.61NS
CAPPP81999Hypertensive (n = 10,985)6.1Captopril vs DIUs/β-blockers162/100Captopril; BP higher 2/2NAMI, stroke, CV death1.050.90–1.2243% higher incidence of stroke in captopril group.004
STOP-291999Hypertensive (n = 4418)4.6ACEIs vs conventional194/98NSNACV death1.010.84–1.22NoneNS
LIFE102002Hypertensive (n = 9193)4.8Losartan vs atenolol174/98Losartan; SBP lower 1.1.017CV death, stroke, MI0.870.77–0.9825% stroke reduction in losartan group.001
ALLHAT112002/2003Hypertensive (n = 24,309)4.9Chlorthalidone vs lisinopril146/84Lisinopril SBP higher 2<.001Fatal CHD, nonfatal MI0.990.91–1.08Lisinopril group: 15% higher stroke.02
19% higher HF<.001
ANBP-2122003(n = 26,083)4.1ACEIs vs DIUs168/91NSNACVS event total mortality0.890.79–1.00In men, RR = 0.83.02
In women, RR = 0.98;.98
JMIC-B132004Hypertensive (n = 1650)3ACEIs vs nifedipine145/82ACEI BP higher 4/1<.01Cardiac event1.050.81–1.37ACEI group coronary lumen narrowedNS
VALUE142004Hypertensive (n = 15,245)4.2Amlodipine vs valsartan155/88Valsartan BP higher 2.1/1.7<.0001CV event1.040.94–1.15Valsartan group 19% higher MI.02
  • * Trials should show (1) no significant difference in primary endpoint in most studies and (2) the group with lower blood pressure had lower adverse clinical outcome regardless of strategy.

  • P = .021.

  • P = .05.

  • Cli diab, clinical diabetes; DIUs, diuretics; ACEIs, angiotensin-converting enzyme inhibitors; NS, not significant; NA, not available; BP, blood pressure; MI, myocardial infarction; CV, cardiovascular; SBP, systolic blood pressure; CHD: coronary heart disease; UKPDS, United Kingdom Prospective Diabetes Study Group; CAPPP, Captopril Prevention Project; STOP-2, Swedish Trial in Old Patients with Hypertension 2; LIFE, Losartan Intervention For Endpoint Reduction in Hypertension Study; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ANBP-2, Second Australian National Blood Pressure Study Group; JMIC-B, Japan Multicenter Investigation for Cardiovascular Diseases-B randomized trial; VALUE, Valsartan Antihypertensive Long-Term Use Evaluation; RR, relative risk; HF, heart failure.